Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.46 |
| ▸ | PDE4A | P27815 | 2/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3217780 | 1.00 | PDE4B (0.46) | PDE4BPDE4APDE4CPDE4DERBB2 | |
| SCHEMBL3219859 | 0.90 | PDE4D (0.45) | PDE4BPDE4APDE4CPDE4DERBB2 | |
| SCHEMBL3219848 | 0.90 | PDE4D (0.45) | PDE4BPDE4APDE4CPDE4DERBB2 | |
| SCHEMBL3903784 | 0.84 | PDE4B (0.49) | PDE4BPDE4APDE4CPDE4DGPR119 | |
| SCHEMBL3206840 | 0.83 | PPARG (0.58) | PDE4BPDE4APDE4CPDE4DERBB2 | |
| SCHEMBL3206854 | 0.83 | PPARG (0.58) | PDE4BPDE4APDE4CPDE4DERBB2 | |
| SCHEMBL3202842 | 0.83 | HDAC8 (0.43) | PDE4BPDE4APDE4CPDE4DERBB2 | |
| SCHEMBL3202826 | 0.83 | HDAC8 (0.43) | PDE4BPDE4APDE4CPDE4DERBB2 | |
| SCHEMBL3904350 | 0.81 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4DERBB2 | |
| SCHEMBL23465733 | 0.80 | GPR119 (0.62) | PDE4BPDE4APDE4CPDE4DGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| EP-1912645-A2 | THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
| WO-2007018314-A2 | THERAPEUTIC AGENT FOR DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PDE4B 444/4885PDE4A 251/4885PDE4C 562/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | PDE4B 738/4885PDE4A 345/4885PDE4C 941/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PDE4B 444/4885PDE4A 251/4885PDE4C 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.